BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 1679963)

  • 1. Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines.
    Tyson FL; Boyer CM; Kaufman R; O'Briant K; Cram G; Crews JR; Soper JT; Daly L; Fowler WC; Haskill JS
    Am J Obstet Gynecol; 1991 Sep; 165(3):640-6. PubMed ID: 1679963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.
    Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E
    Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer.
    Hung MC; Zhang X; Yan DH; Zhang HZ; He GP; Zhang TQ; Shi DR
    Cancer Lett; 1992 Jan; 61(2):95-103. PubMed ID: 1346099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplification of protooncogenes in surgical specimens of human lung carcinomas.
    Shiraishi M; Noguchi M; Shimosato Y; Sekiya T
    Cancer Res; 1989 Dec; 49(23):6474-9. PubMed ID: 2573414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of protooncogenes in human germ cell tumors of the testis.
    Shuin T; Misaki H; Kubota Y; Yao M; Hosaka M
    Cancer; 1994 Mar; 73(6):1721-7. PubMed ID: 7908857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.
    Guérin M; Barrois M; Terrier MJ; Spielmann M; Riou G
    Oncogene Res; 1988; 3(1):21-31. PubMed ID: 2905033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
    Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
    Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated c-myc messenger RNA in multiple myeloma cell lines.
    Fourney R; Palmer M; Ng A; Dietrich K; Belch A; Paterson M; Brox L
    Dis Markers; 1990; 8(3):117-24. PubMed ID: 1980237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different pattern of expression of cellular oncogenes in human non-small-cell lung cancer cell lines.
    Kiefer PE; Wegmann B; Bacher M; Erbil C; Heidtmann H; Havemann K
    J Cancer Res Clin Oncol; 1990; 116(1):29-37. PubMed ID: 1690210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic alterations in c-erbB-2 protooncogene as prognostic markers in human primary breast tumors.
    Nagai MA; Marques LA; Torloni H; Brentani MM
    Oncology; 1993; 50(6):412-7. PubMed ID: 7901824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amplification and expression of protooncogenes in human small cell lung cancer cell lines.
    Kiefer PE; Bepler G; Kubasch M; Havemann K
    Cancer Res; 1987 Dec; 47(23):6236-42. PubMed ID: 2824028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
    Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogene patterns in breast and ovarian carcinomas.
    Csókay B; Papp J; Besznyák I; Bösze P; Sárosi Z; Tóth J; Zalay Z; Oláh E
    Eur J Surg Oncol; 1993 Dec; 19(6):593-9. PubMed ID: 7903645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amplification of the C-erbB-2(HER-2/neu) proto-oncogene in ovarian carcinomas.
    Fan QB; Bian ML; Huang SZ; Lang JH; Ma J; Liu WS; Xu XY
    Chin Med J (Engl); 1994 Aug; 107(8):589-93. PubMed ID: 7805442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amplification of the HER-2/neu protooncogene in human endocrine tumors.
    Evers BM; Rády PL; Tyring SK; Sanchez RL; Rajaraman S; Townsend CM; Thompson JC
    Surgery; 1992 Aug; 112(2):211-7; discussion 217-8. PubMed ID: 1353638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-myc, N-myc, N-ras, and c-erb-B: lack of amplification or rearrangement in human medullary thyroid carcinoma and a derivative cell line.
    Yang KP; Castillo SG; Nguyen CV; Hickey RC; Samaan NA
    Anticancer Res; 1990; 10(1):189-92. PubMed ID: 2185686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protooncogene amplification and tumor ploidy in human ovarian neoplasms.
    Sasano H; Garrett CT; Wilkinson DS; Silverberg S; Comerford J; Hyde J
    Hum Pathol; 1990 Apr; 21(4):382-91. PubMed ID: 1969381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer.
    Yao M; Shuin T; Misaki H; Kubota Y
    Cancer Res; 1988 Dec; 48(23):6753-7. PubMed ID: 2460228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The relation between prognosis and amplification of the c-erB-2 (HER-2/neu) proto-oncogene in ovarian carcinomas].
    Fan QB; Bian ML; Huang SZ
    Zhonghua Yi Xue Za Zhi; 1994 Nov; 74(11):683-5, 710. PubMed ID: 7866905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogene abnormalities in astrocytomas: EGF-R gene alone appears to be more frequently amplified and rearranged compared with other protooncogenes.
    Burgart LJ; Robinson RA; Haddad SF; Moore SA
    Mod Pathol; 1991 Mar; 4(2):183-6. PubMed ID: 1675468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.